Carboprost Tromethamine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Carboprost Tromethamine
- Carboprost Tromethamine: From Obstetric Use (Indication Not Stated in the Local Record) to Atypical Coarctation of Aorta
Carboprost Tromethamine: From Obstetric Use (Indication Not Stated in the Local Record) to Atypical Coarctation of Aorta
One-Sentence Summary
Carboprost tromethamine is a 15-methyl prostaglandin F2α analogue, registered in Singapore as an injectable product (HEMABATE); the registration record does not list an approved indication. The TxGNN model predicts it may be effective for atypical coarctation of aorta with a very high score, but there are 0 clinical trials and 0 publications supporting this direction. The prediction rests on the model alone and has no biological or clinical backing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore registration record |
| Predicted New Indication | Atypical coarctation of aorta |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled record. Based on known pharmacology, carboprost is a 15-methyl PGF2α analogue that acts as an FP receptor agonist, causing smooth muscle contraction and vasoconstriction. It is known clinically for its action on the uterus (myometrial contraction).
That mechanism does not fit this prediction. Atypical coarctation of aorta is a structural congenital defect of the vessel, and a drug would not correct an anatomical narrowing. Vasoconstriction offers no therapeutic rationale here. The high TxGNN score is best read as a model artefact, not a signal of real benefit.
The other top-ranked predictions are also weak. Of the 10 predictions reviewed, all are evidence level L5 with no trials or literature, and all are rated Hold:
| Rank | Predicted Disease | TxGNN Score | Assessment |
|---|---|---|---|
| 1 | Atypical coarctation of aorta | 99.99% | Structural defect; no pharmacological rationale |
| 2 | Aortic malformation | 99.98% | Surgical or interventional condition; no rationale |
| 3 | Migraine with brainstem aura | 99.97% | FP agonism likely neutral or pro-nociceptive; nausea and vomiting unfavourable |
| 4 | Migraine disorder | 99.96% | Same as above |
| 5 | Pulmonary hypertension | 99.93% | Carboprost raises pulmonary vascular resistance, so it may worsen the disease |
| 6 | Non-syndromic esophageal malformation | 99.92% | Needs surgical correction; no rationale |
| 7 | Kyphoscoliotic heart disease | 99.92% | Pulmonary vasoconstriction could be harmful |
| 8 | Amenorrhea | 99.89% | Loose link to reproductive physiology; speculative |
| 9 | Esophageal disease | 99.83% | Gastrointestinal smooth muscle stimulation may aggravate symptoms |
| 10 | Primary hereditary glaucoma | 99.69% | Class-level rationale (FP agonists lower eye pressure), but no ocular formulation or data, and established agents already fill this niche |
Primary hereditary glaucoma is the most biologically plausible of the group, but only through other drugs in the same class, not carboprost itself.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN06722P | HEMABATE INJECTION 250 mcg/ml | Injection | Not stated in the registration record |
The product is a single-ingredient injection from Pharmacia & Upjohn Company LLC, and its registration is valid.
Safety Considerations
- Drug Interactions: The interaction query returned no records.
- Pharmacological concerns (from the mechanism assessment): Carboprost can cause pulmonary vasoconstriction and raise pulmonary arterial pressure, which is a concern in pulmonary hypertension and related cardiopulmonary conditions. It also commonly causes nausea, vomiting, and diarrhoea.
Warnings and contraindications from the package insert were not available for this report. Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials or literature behind it. The drug's vasoconstrictive mechanism runs counter to any plausible benefit in a structural aortic defect, and for pulmonary hypertension it may cause harm. None of the ten predicted indications has enough support to proceed.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA), which are required before any safety screening
- The approved indication text for the registered product
- Detailed mechanism of action data
- If any indication is pursued, glaucoma is the only one with a class-level rationale, and it would need a dedicated ocular formulation and direct preclinical or clinical data. Established FP agonists already serve that need, so added value is likely small.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.